These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26517374)

  • 1. A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor.
    Mao Y; Peng Y; Zeng Q; Cheng L; Wang B; Mao X; Meng K; Liu Y; Lian Y; Li D
    PLoS One; 2015; 10(10):e0141464. PubMed ID: 26517374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human platelets express functional thymic stromal lymphopoietin receptors: a potential role in platelet activation in acute coronary syndrome.
    Wang B; Peng Y; Dong J; Lin J; Wu C; Su Y; Fang H; Wang L; Huang K; Li D
    Cell Physiol Biochem; 2013; 32(6):1741-50. PubMed ID: 24356513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory cytokine TSLP stimulates platelet secretion and potentiates platelet aggregation via a TSLPR-dependent PI3K/Akt signaling pathway.
    Dong J; Lin J; Wang B; He S; Wu C; Kushwaha KK; Mohabeer N; Su Y; Fang H; Huang K; Li D
    Cell Physiol Biochem; 2015; 35(1):160-74. PubMed ID: 25591759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
    Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
    J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the TSLP-TSLPR-LAP signaling between epithelial and dendritic cells through hyperlipidemia contributes to regulatory T-Cell defects in atherosclerotic mice.
    Yu K; Dong Q; Mao X; Meng K; Zhao X; Ji Q; Wu B; Zhong Y; Zhu Z; Liu Y; Zhang W; Tony H; Shi H; Zeng Q
    Atherosclerosis; 2015 Feb; 238(2):278-88. PubMed ID: 25544178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockage of thymic stromal lymphopoietin signaling improves acute lung injury in mice by regulating pulmonary dendritic cells.
    Pan G; Liang Y; Lu L; Chen X; Wang M; Wang L; Yan C; Zhang W
    Int J Clin Exp Pathol; 2015; 8(9):10698-706. PubMed ID: 26617780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
    Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
    Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
    Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
    J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
    Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
    Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice.
    Liu X; Zhao G; Yan Y; Bao L; Chen B; Qi R
    PLoS One; 2012; 7(5):e36237. PubMed ID: 22662117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery.
    Hansson EC; Malm CJ; Hesse C; Hornestam B; Dellborg M; Rexius H; Jeppsson A
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):633-637. PubMed ID: 28007881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymic stromal lymphopoietin is a key cytokine for the immunomodulation of atherogenesis with Freund's adjuvant.
    Steinmetz M; Laurans L; Nordsiek S; Weiß L; van der Veken B; Ponnuswamy P; Esposito B; Vandestienne M; Giraud A; Göbbel C; Steffen E; Radecke T; Potteaux S; Nickenig G; Rassaf T; Tedgui A; Mallat Z
    J Cell Mol Med; 2020 May; 24(10):5731-5739. PubMed ID: 32285594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
    Li H; Guo J; Carlson GF; Teng R
    Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
    Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B
    Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
    Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
    J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis.
    Preusch MR; Rusnak J; Staudacher K; Mogler C; Uhlmann L; Sievers P; Bea F; Katus HA; Blessing E; Staudacher I
    Drug Des Devel Ther; 2016; 10():2691-9. PubMed ID: 27616880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
    Xue HJ; Shi J; Liu B; Wang DY; Dong ZX; Guo H; Kong YH; Sheng L; Shao Q; Sun DH; Zhang L; Pan YJ; Dong XW; Li JQ; Xue JY; Zhou YY; Yang HP; Li Y
    Platelets; 2016 Jul; 27(5):440-5. PubMed ID: 26830862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.